Noetic Fund

Diamond Therapeutics is a Toronto-based psychedelic drug development company dedicated to creating innovative therapies for mental health conditions. The company aims to harness the potential of psychedelic compounds, specifically focusing on sub-perceptual, non-hallucinogenic treatments that can be safely administered at home. By prioritizing these types of therapies, Diamond seeks to address the needs of a diverse patient population and enhance the efficacy of mental health treatments. The company’s approach includes psychopharmacology and biotechnology, with an emphasis on developing psilocybin-based medicines that may offer improved outcomes compared to existing first-line treatments, ultimately contributing to a positive impact on the global mental health crisis.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company focused on treating and preventing cognitive deficits associated with various brain disorders and aging. The company develops small molecule therapeutics aimed at transforming the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Their goal is to enable patients to potentially reverse impairments and resolve previously unresolvable symptoms.

Woven Science is a life sciences platform focused on creating a comprehensive solution for mental healthcare, particularly through psychedelic therapeutics. The company aims to establish one of the first vertically integrated patient care systems in this field, encompassing all stages from drug development to clinic distribution. Woven Science emphasizes a model of mutuality, balancing purpose and profit, and is notable for its commitment to social responsibility by allocating 10% of its realized profits to nonprofits dedicated to supporting indigenous culture and ecosystem preservation. By building, backing, and incubating innovative companies within its ecosystem, Woven Science seeks to address the mental illness epidemic with a focus on delivering scalable and effective mental health outcomes throughout the treatment process.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

Eleusis is a clinical stage life science company focused on harnessing the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics. The company aims to develop innovative psychedelic drug therapies that address unmet medical needs, particularly in the field of psychiatry and beyond. Eleusis is advancing a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. By doing so, the company seeks to provide healthcare providers and pharmaceutical companies with viable alternatives to conventional therapies, thereby broadening the scope of treatment options available to patients.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.